Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases (MIROX)
Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
This PHASE3 trial investigates Chemotherapy and Colorectal Cancer and is currently completed. GERCOR - Multidisciplinary Oncology Cooperative Group leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2018 [monthly]
Completed PHASE3
First recorded
Jul 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Avignon, France , Beauvais, France , Bordeaux, France , Boulogne-Billancourt, France , Boulogne-sur-Mer, France , Briey, France , Caen, France , Chartres, France , Clichy, France , Colombes, France and 17 more locations